NASDAQ · Biotechnology

ANIX (ANIX) Stock

$3.48 -1.14% NASDAQ: ANIX Healthcare

Valuation

MetricValue
Price$3.48
Market Cap$118.40M
P/E Ratio-8.00
P/B Ratio6.07
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$5.46
52-Week Low$2.44
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-73.33%
ROA-68.75%
ROCE-85.71%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.01
Current Ratio8.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.0M$0$0$0$0
Operating Profit$-13.0M$-14.0M$-11.0M$-14.0M$-12.0M
Net Profit$-13.0M$-14.0M$-10.0M$-13.0M$-11.0M
EPS$-0.45$-0.45$-0.32$-0.39$-0.34
Op Margin-2565.6%—-5243.3%——

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$36.0M$30.0M$26.0M$22.0M$16.0M
Total Liabilities$1.0M$2.0M$2.0M$3.0M$2.0M
Cash$29.0M$12.0M$1.0M$1.0M$1.0M
Borrowings$0$0$0$0$0

Latest News

Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date PR Newswire · Jul 6, 2026 Anixa Biosciences secures Korean patent for breast cancer vaccine Pharmaceutical Technology · Jun 30, 2026 Anixa Biosciences Granted Korean Patent for Breast Cancer Vaccine MT Newswires · Jun 29, 2026 Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040 PR Newswire · Jun 29, 2026 Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium PR Newswire · Jun 26, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-5.0M$-6.0M$-6.0M$-7.0M$-7.0M
Investing Cash Flow$-4.0M$-11.0M$-6.0M$4.0M$5.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$23.0M$-17.0M$-11.0M$0$0
Free Cash Flow$-5.0M$-6.0M$-6.0M$-7.0M$-7.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-7.46%
Quick Ratio12.18
Interest Coverage—
Return 1Y2.34%
Return 3Y-10.03%
Return 5Y-17.71%

Ownership

Insiders Held5.39%
Institutions Held15.11%
Institutions Float Held15.98%
Institutional HolderSharesReport Date
Vanguard Capital Management LLC1,314,9822026-03-31
Laird Norton Wetherby Trust Company, LLC566,3272026-03-31
UBS Group AG551,6372026-03-31
D.A. Davidson & Co.539,2722026-03-31
Geode Capital Management, LLC364,7312026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABOS $2.27 -0.66% -1.17 $163.60M 0.00%
ACTU $1.09 -5.22% -2.73 $26.08M 0.00%
AGENAgenus Inc. $6.06 +1.34% 3.46 $252.35M 0.00%
ENTX $2.87 +1.77% -4.96 $141.46M 0.00%
HURA $2.09 -2.34% -3.75 $133.10M 0.00%

About ANIX

ANIX is led by CEO Amit Kumar, employs 5 people, headquartered in US, publicly traded since 1983.

ANIX stock trades at $3.48 with a market capitalization of $118.40M. The stock is valued at a price-to-earnings (P/E) ratio of -8.00, price-to-book of 6.07, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.44 and $5.46, and currently trades 36.3% below its 52-week high.

On profitability, ANIX generates a return on equity (ROE) of -73.33%, return on capital employed of -85.71%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides